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HIV broadly neutralizing antibodies (bnAbs) can suppress viremia and protect against HIV
infection. However, their elicitation is made difficult by low frequencies of appropriate pre-
cursor B cell receptors and the complex maturation pathways required to generate bnAbs
from these precursors. Antibody genes can be engineered into B cells for expression as both a
functional antigen receptor on cell surfaces and as secreted antibody. Here, we show that
HIV bnAb-engineered primary mouse B cells can be adoptively transferred and vaccinated in
immunocompetent mice resulting in the expansion of durable bnAb memory and long-lived
plasma cells. Somatic hypermutation after immunization indicates that engineered cells have
the capacity to respond to an evolving pathogen. These results encourage further exploration
of engineered B cell vaccines as a strategy for durable elicitation of HIV bnAbs to protect
against infection and as a contributor to a functional HIV cure.
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Critical support for efforts to design an HIV vaccine thatwould elicit broadly neutralizing antibodies (bnAbs)comes from experiments that show such antibodies are
capable of providing sterilizing immunity against clinically rele-
vant (so-called Tier 2) virus challenge in macaque and humanized
mouse models1–3. Genetic limitations imposed by the human
repertoire of B cell antigen receptors (BCRs) from which such
antibodies must arise, has however significantly impeded these
efforts. Characterization of a variety of bnAbs discovered in
chronically infected patients shows that they generally derive
from B cell precursors with uncommon antigen receptor features,
such as long third heavy chain (HC) complementarity deter-
mining regions (CDRH3s), and then require extensive somatic
hypermutation to facilitate broad neutralization3,4. Mature HIV
bnAbs and other desirable antibody genes can be directly added
to the repertoire by engineering them into the genomes of ex vivo
activated primary B cells for expression as functional BCRs using
endogenous HC constant genes5–7. As such, engineered BCRs can
undergo class switching for eventual secretion as protective
antibodies from plasma cells. B cells engineered in this way have
been shown to confer protective levels of pathogen-specific
antibody in vivo for several weeks following adoptive transfer into
immunocompromised mice7, or for several days following
transfer into immunocompetent wild type (WT) mice6,7. Vaccine
elicitation of durable HIV bnAb responses from engineered B
cells in immunocompetent hosts would be an attractive con-
tributor to a functional HIV cure, given that bnAbs administered
passively in the context of infection have been shown to suppress
viremia, kill infected cells, and enhance host immunity8–10. Here,
we show that HIV bnAb-engineered primary B cells can be
expanded and affinity-matured in vivo through vaccination,
resulting in durable bnAb memory and long-lived plasma cells in
wild-type mice.
Results
Modified primary B cells express the HIV VRC01 bnAb as
antigen receptor. Wild-type (WT) C57BL/6J (or B6) mice are a
useful model in which to explore vaccine elicitation of HIV
bnAbs from engineered cells because of similarities between the
mouse and human humoral immune systems, and because such
bnAbs cannot be elicited from the natural repertoire11–13. We
therefore developed methods to knock the VRC01 HIV bnAb into
mature primary C57BL/6J B cells. We chose VRC01 because this
prototype CD4 receptor binding-site bnAb has been extensively
tested in the clinic for its ability to suppress viremia in patients
and prevent infection after administration as a recombinant
monoclonal antibody14–16 (clinicaltrials.gov NCT02568215,
NCT02716675). In our first genome editing strategy, donor DNA
carrying a V-gene promoter, the VRC01 HIV bnAb17,18 light
chain (LC), HC variable region (VDJ), and constant gene splice
donor site, are introduced into a CRISPR-cas9 DNA break-site in
the IgH-J4 gene using homology-directed repair (HDR) in acti-
vated cells. Here, the inserted VRC01 genes are expressed from a
single mRNA, transcript spliced to downstream endogenous IgH
constant genes. A P2A self-cleaving peptide sequence down-
stream of the VRC01 mouse kappa (κ) constant gene separates
the light and HCs, allowing them to pair and form a functional
cell surface-expressed BCR (H-targeting) (Fig. 1a). A second
engineering strategy was also employed, in which the VRC01
heavy and κ variable regions were targeted separately to their
endogenous loci for expression from V-gene promoter-controlled
transcripts spliced to cell-native H or κ constant genes (H+ κ
targeting) (Fig. 1b). Targeting success in primary B cells was
monitored using HIV envelope glycoprotein-based flow cyto-
metry probes that specifically recognize VRC01: eOD-GT8 is an
‘engineered outer domain’ of gp120 that presents the CD4-
binding site and has a KD= 16 pM monovalent affinity to
VRC01; KO11 carries a single amino acid substitution that
knocks out VRC01 binding19,20. Targeting by H or H+ κ stra-
tegies routinely resulted in engineering efficiencies of 10% and
1%, respectively when plasmid donor DNA and CRISPR-cas9
ribonucleoprotein (RNP) was delivered to LPS-activated cells
using electroporation (Fig. 1c, Supplementary Fig. 1). While less
toxicity was observed when adeno-associated viral (AAV) vector
donor DNA was transduced into cells after RNP electroporation
(Supplementary Fig. 1), we preferred plasmid donors as targeting
efficiencies were comparable, and because this format allowed for
quick and inexpensive development of a large number of donor
DNAs for testing. Cutting efficiencies of the IgH-J4 and IgK-J5
RNPs were 80 and 55% by TIDE analysis21 (Supplementary
Fig. 1b). Off-target repair of these DNA breaks should either be
inert or generate BCR knockouts which will lead to cell apoptosis.
Translocation of the telomeric ends of mouse chromosomes 12
and 6 (involving the two cuts generated in H+ k targeted cells)
would also lead to a loss of BCR expression and cell apoptosis.
Ex vivo targeted B cells return to rest as self-tolerant memory
in vivo. These engineering strategies can result in the expression
of self-reactive BCRs due to pairing of engineered Ig chains with
those endogenously produced by the targeted cell5–7. This is
especially true for H-targeted cells which present native LCs on
the surface of at least 34% of VRC01-expressing cells (Supple-
mentary Fig. 2a). While tolerance mechanisms in the periphery of
mice and humans generally ensure that autoreactive B cells are
non-functional22–25, we sought to ensure that this would still be
the case for engineered B cells which require an ex vivo lipopo-
lysaccharide (LPS) activation step in order to achieve efficient
HDR based genome editing. We therefore transferred WT
untouched, or ex vivo LPS-activated B cells into transgenic mice
expressing an Igκ chain-reactive super-antigen on the surface of
hepatocytes (pAlb mice)26. In this context, all donor Igκ+ B cells
would be autoreactive. After 28 days in this host, both the
untouched and LPS-activated Igκ+ cells were deleted suggesting
that auto-reactive B cells generated during the engineering step
should remain subject to peripheral tolerance mechanisms in vivo
(Supplementary Fig. 2b, c).
B cells purified from the spleens of WT donor mice by negative
selection were then activated with LPS, targeted, and transferred
into WT recipients to assess their status after 14 days in vivo.
Untouched donor B cells that were directly transferred into
control mice had low frequencies of memory B cells (MBCs),
whereas 70-80% of ex vivo targeted cells acquired a germinal
center (GC)-independent (CD73−) memory phenotype27,28
(Fig. 1d–f, Supplementary Fig. 3). The serendipitous effect of
generating memory after 14 days in vivo as a result of ex vivo LPS
activation for genome editing suggests engineered B cells should
be optimally poised for vaccination at this timepoint.
Durable VRC01 serum titers can be elicited from H-targeted
cells by vaccination. After targeting using either the H or H+ κ
engineering strategies, 40,000 VRC01 BCR-expressing cells were
engrafted per animal into WT recipient mice. This corresponds to
~3 in 100,000 B cells present after parking for 14 days in vivo
(Supplementary Fig. 3b). Mice with either mock-targeted, H+ K
targeted, or H-targeted B cells were primed 14 days post
cell transfer (w0) with MD39-ferritin, a soluble stabilized
HIV envelope native trimer multivalently presented on a ferritin-
based nanoparticle. MD39 has a monomeric affinity for VRC01
of KD= 124 nM29,30. Mice were boosted 6 weeks (w6) after a
prime. Three mice engrafted with H-targeted cells involved in a
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longer-term study were further boosted 13 and 32 weeks after the
prime (Fig. 2a). Total antigen-specific and engineered antibody
responses were tracked in the serum by ELISA and using virus
neutralization assays. Mice that received mock engineered or
H+ κ targeted cells elicited the lowest total antigen-specific
and VRC01-competitive antibody responses. Mice that received
H-targeted cells showed on average 10-fold higher total antigen-
specific titers one week after the first boost and this was
accompanied by significantly higher levels of VRC01-competitive
antibody in the serum (Fig. 2b, c). Because some VRC01-
competing antibody responses could be elicited in control
mice with mock-targeted cells, VRC01 in the serum of mice
containing H-targeted cells was also measured by P2A ELISA, as
VRC01 κ chains expressed from these cells are tagged with a P2A
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Fig. 1 Engineering primary B cells and adoptive transfer of cells to WT mice. a Targeting antibody genes to the mouse heavy chain (HC) locus (H-
targeting). Donor DNA encoding (1) a HC V-gene promoter, (2) the VRC01 κ chain (with mouse constant gene and P2A peptide), (3) the VRC01 HC
variable (VDJ) region and donor splice site is inserted at a CRISPR-Cas9 cut site in JH4 for expression as a functional antigen receptor using endogenous
downstream HC constant genes. Regions of homology (HR) flanking bnAb donor-DNA allow for its incorporation at the DNA break-site by homology-
directed repair (HDR). b Targeting antibody genes to the mouse heavy and kappa loci (H+ κ targeting). To engineer the IgH locus, donor DNA encoding (1)
a HC V-gene promoter (2) VRC01 VDJ gene, and constant gene donor splice site is inserted as above. To engineer the Igκ locus, donor DNA encoding (1) a
κ V-gene promoter, (2) VRC01 κ variable (VJ) region and constant gene donor splice site is likewise inserted into a CRISPR-Cas9 cut site in Jκ5, for
expression of VRC01 H and κ chains from their endogenous loci spliced to cell-native constant genes. c Targeting efficiency. Successfully targeted B cells
expressing VRC01 as cell surface antigen receptor were detected as live, single, KO11−,eOD-GT8-AF647+, and eOD-GT8-AF488+ cells by flow cytometry.
eOD-GT8 double-positive cells are shown for LPS activated (mock), H+ κ, and H-targeted B cell cultures. d LPS-activated donor cells acquire a memory
phenotype in vivo after adoptive transfer. Non-engineered primary B cells were either directly transferred or cultured for 48 h in LPS before adoptive
transfer into host mice. The fractions of donor (CD45.1+) cells that showed a memory cell (MC) phenotype after 14 d in vivo are shown for n= 6 mice in
each group. Memory B cells are gated as live CD19+CD38+GL7−IgD−. e Engineered cells become germinal center independent (CD73−) memory in vivo.
H-targeted cells were adoptively transferred into host mice. 14 days later, successfully engineered (GT8+) cells were analyzed by flow cytometry. Host
naïve and memory B cell populations are compared for their expression of CD73, PD-L2, and CD80 memory markers. f Quantitation of B cells gated as in
(e). The fraction of successfully targeted cells with the indicated cell surface memory cell markers are given for n= 4 engrafted mice. These are compared
with unsuccessfully engineered cells in the targeted population (GT8−), mock engineered, or host cell controls. Data are presented as mean value ± SD in
Figure d and f.
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self-cleaving peptide at the C terminus. Mice with H-targeted cells
elicited P2A titers after each boost (Fig. 2d, Supplementary
Fig. 4). The highest responder (H-6), produced ~2.4 mg/ml of
VRC01 in the serum one week following the third boost calcu-
lated using a recombinant LC P2A-tagged VRC01 mouse
IgG1 standard (Fig. 2e, Supplementary Fig. 4). IgG purified from
sera of these mice also showed VRC01-like neutralization of HIV
pseudoviruses from different clades that bear hallmarks of typical
circulating viruses, such as relative neutralization resistance31
(Fig. 2f, Supplementary Fig. 5). Because no neutralizing responses
could be elicited to a strain particularly sensitive to VRC01
neutralization (BG505-N276A) in mice with mock-targeted cells,
IC50s for this pseudovirus were used to quantify functional
VRC01 as a fraction of total serum IgG in responding mice using
the recombinant LC P2A-tagged VRC01 mouse IgG1 standard. In
the best responder (H-6), serum VRC01 constituted ~0.15% of
the total IgG even after a 5-month rest period (w32) and this was
boosted to ~10% of the total IgG by one week after the third boost
(Fig. 2g, Supplementary Fig. 5). We conclude that H-targeted
engineered B cells can generate durable memory and serum
antibody in the immunocompetent B6 mouse model. Further
investigation is required to understand why H+ κ targeted cells
failed to respond detectably to vaccination.
Immunized VRC01-B cells mature into GC-dependent mem-
ory and plasma cells. Consistent with the serum analysis, two
weeks after the first boost, only mice that received H-targeted cells
showed high frequencies of VRC01-engineered GC B cells
(Fig. 3a-c), splenic and bone marrow plasma cells (Fig. 3d, e) and
MCs (Fig. 3f). Engineered cells in mice from this group were
expanded 20–70-fold during the prime and boost (Fig. 3g) and
VRC01-expressing memory (GT8++, KO11−, donor+) cells
became mostly CD73+, implying their entry into GCs after vac-
cination, unlike GT8− donor cells, which remained CD73− after
LPS treatment (Fig. 3h, i).
Repeat experiments and variations on the original protocol also
successfully elicited VRC01 memory responses in other groups of
mice with H-targeted cells (Supplementary Table 1). Variations
included: (1) FACS enrichment of only antigen-specific engi-
neered cells before transfer; (2) ex vivo activation of B cells using
CD40L, IL-4, and other MyD88 inducers such as CpG DNA
(rather than LPS); (3) alternative immunization strategies in
which engineered cells were primed coincident with transfer into
mice with pre-existing immunogen-specific T cell help, and; (4)
immunization using different adjuvants.
Coding mutations are selected in VRC01 genes after vaccina-
tion. Engineered immunoglobulin gene repertoires from the
spleen (memory) and bone marrow (long-lived plasma cell)
compartments were sequenced in several mice with H-targeted
cells 35 days after their final boosts. Repertoires mostly conserved
the original VRC01 amino acid sequence, however an abundance
of variants with coding changes were present, including some
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Fig. 2 Serological analysis of VRC01 responses after vaccination. a Engineered B cell vaccine experimental design. Time course of B cell engineering, cell
transfer, immunization, and blood sampling in WT C57BL/6J mice. b–d Serum antibody responses after MD39-ferritin immunization in mice that received
mock targeted, H-targeted, or H+ κ targeted B cells. Titers (y-axis) are given for the indicated timepoints (x-axis) and mice (legend): b Total (host+ donor)
IgG response to the immunogen, given as serum dilution factor (SDF) EC50s; c VRC01-competetive antibody responses given as the transformed area
under the curve (AUC) and; d Serum IgG carrying the P2A tag on engineered L-chains, given as area under the curve (AUC). e µg/ml VRC01 in the serum.
The quantity of VRC01 in the indicated serum samples at the indicated timepoints was calculated using a recombinant mouse VRC01-P2A-tagged IgG
standard. n= 3-4 mice per group in n= 2 experiments. f Serum neutralization of HIV. IgG purified from the serum of the indicated mice at the indicated
timepoints was tested for its ability to neutralize HIV pseudoviruses using the TZM-bl assay. Percent neutralization of virus achieved by 200 µg/ml of IgG
is given as a heat map for several tier-2 viruses from different clades (BGN= BG505) when neutralization decreases with IgG concentration. g VRC01
antibody as a fraction of the total serum IgG. The fraction of total serum IgG with functional VRC01 activity was assessed for the indicated mice at the
indicated timepoints (weeks post-prime) by comparing the BG505-N276A neutralization IC50 values for these samples with the recombinant mouse
VRC01-P2A-tagged IgG. n= 3-4 mice per group in n= 2 experiments. Data are presented as mean value ± SD in (e) and (g).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19650-8
4 NATURE COMMUNICATIONS |         (2020) 11:5850 | https://doi.org/10.1038/s41467-020-19650-8 | www.nature.com/naturecommunications
(Fig. 4a). While engineered cells were mostly IgM at the time of
transfer, the VRC01 repertoires after vaccination were almost
completely class switched with IgG1 and IgG2 isoforms dom-
inating as expected (Fig. 4a, b). Mutations in the post-vaccinated
engineered repertoire were few for IgM and IgG3, while the
majority of sequences of all other isotypes were mutated, with
some IgG1 sequences showing as high as 4% divergence from the
original donor DNA sequence (Fig. 4b, Supplementary Fig. 6).
Coding mutations were observed across the entire length of the
engineered VRC01 LC and HC variable regions, especially within
the κ constant gene, which is not normally in the path of the
mutator (Fig. 4c, Supplementary Fig. 7a). Structural modeling
shows that these κ constant mutations mostly occur in solvent-
exposed loops connecting β-strands of the immunoglobulin-fold
and would be functionally innocuous (Supplementary Fig. 7b).
Coding changes in the P2A peptide were strikingly absent as this
sequence must be highly conserved in order to express a func-
tional BCR in engineered cells. Identical mutations could be
observed across compartments and animals, and some coding
changes appeared enriched in one compartment over the other
within the same animal (Fig. 4c). The HC CDR2 region of
VRC01, which forms the primary interaction surface of this
antibody with the virus17, showed coding changes after vaccina-
tion (Fig. 4d) indicating that engineered responses generate some
variation in antigen-binding specificity which could be advanta-
geous against highly diverse viral reservoirs and confirming the
ability of engineered B cells to undergo somatic mutation and
affinity maturation.
In the first demonstration of antibody activity, Behring and
Kitasato showed in 1890 that serum from immunized mice could
protect naive ones from lethal challenge of Diptheria and Tetanus
toxins. We show here, and in the complementary study by
Nahmed et al.32, that it is possible to passively transfer genetic
information to the adaptive immune system that facilitates a high
affinity, highly evolved, yet further evolvable, HIV bnAb response
—in effect, demonstrating that one can program immune
memory. Thus, we envision that our study represents a new
phase in the development of passive immunity, started with the
discovery of the antibody itself.
Methods
Cell culture. 293T cells for HIV pseudovirus production were obtained from the
American Type Culture Collection (ATCC, #CRL-3216) and cultured in DMEM
(Invitrogen, #10313021) supplemented with; 10% fetal bovine serum (Invitrogen,
5 GC B cells
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Host naive B cells
Fig. 3 Flow cytometric analysis of antigen-matured engineered B cells. Host mice receiving LPS activated only (Mock), H+ κ, or H -targeted B cells were
analyzed 14 d after the first boost (w8). n= 4 mice in each group. a–c, Germinal center (GC) B cells. a Representative flow cytometry and statistical analysis
of total GC B cells pre-gated as live, CD19+ singlets. b CD45.1+ (donor) GC B cells. c Fraction of cells gated in (b) which were class-switched IgG1+
and GT8++KO11− (engineered VRC01-expressing). d–e Plasma cells (PCs). Frequency of class-switched and antigen-specific PCs in the spleen (d) and
bone marrow (e) as a fraction of total donor PCs. GT8++KO11–CD45.1+CD45.2−IgG+ PCs were analyzed by intracellular staining after the permeabilization
of surfaced-stained cells. Plasma cells are gated as F4/80-IgD−TCRβ−CD138+Sca-1+. f Memory cells (MCs). Enumeration of IgG1+GT8++KO11−,
engineered MCs (sIgD−CD45.1+CD45.2−CD38+GL7−). g Vaccine-induced expansion of engineered cells. GT8++KO11−CD45.1+CD45.2− cell expansion
at w8 compared with w0 as a percentage of the total donor cells. h Engineered memory cells have become germinal center dependent (CD73+) after
vaccination. GT8+ or GT8− donor memory cells were compared with host naïve and memory B cell controls for expression of the indicated memory
cell surface markers. i Quantification of B cells memory subtypes gated as in (h). a–i Bars represent mean ± SD for all data points in each group. *P < 0.05;
**P < 0.01; ns, not significant; unpaired 2-tailed T test.
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Fig. 4 Engineered antibody repertoire in vaccinated mice. a Diversity of the engineered repertoire after immunization. Relatedness of VRC01 clonotypes
by isotype (left), and compartment (right), in one representative animal (H-7) 5 weeks after the final boost. b Somatic hypermutation by isotype. Percent
divergence from donor DNA nucleotide sequence is shown for combined engineered repertoires from all compartments and animals sequenced by isotype.
Fewer engineered IgM or IgG3 sequences were obtained and these were mostly unmutated (<5% of sequences), while IgG1, G2B, G2A/C, E, and A were
significantly mutated (>68% of sequences, reaching up to 4% mutated) (Supplementary Fig. 6). Fig. S6). c Mutational hotspots in the engineered VRC01
gene. The frequency of amino acid changes at each residue position across the H-targeted VRC01 gene is shown as a percentage of the total sequences
obtained for each dataset. Six datasets are shown which are derived from both memory and plasma cell compartments from the three indicated mice.
Specific coding changes across the length of the gene are given in Fig. S6 from one representative mouse (H-6). d Antigen-binding properties are
diversified in the engineered repertoire. The fraction of sequences with coding changes from memory (S/L) or plasma cell (BM) compartments are shown
as sequence logos for the CDRH regions in the indicated mice. Blue arrows indicate amino acid positions undergoing diversification.
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#26140-079), 2 mM L-glutamine (Invitrogen, #2503008), 100 units of Penicillin
and 0.1 mg/ml of Streptomycin (Invitrogen, #15140122). TZM-bl cells for virus
neutralization assays were obtained from the National Institutes of Health (NIH)
AIDS Reagent Program (#8129) and cultured in DMEM supplemented with FBS
(10%), 100 units of Penicillin and 0.1 mg/ml of Streptomycin. FreeStyle™ 293F cells
for protein production were obtained from Life Technologies (#R79007) and cul-
tured in FreeStyle™ 293 Expression Medium (Life Technologies, #12338018).
Chemically competent DH5a E. coli for plasmid propagation were purchased from
NEB (#C2987H).
Mice. Mouse studies were approved and carried out in accordance with protocols
provided to the Institutional Animal Care and Use Committee (IACUC) at Scripps
Research (La Jolla, CA) under approval number 18-0004. The mice were housed,
immunized, and bled at Scripps in compliance with the Animal Welfare Act and
other federal statutes and regulations relating to animals in adherence to the Guide
for the Care and Use of Laboratory Animals (National Research Council, 1996). All
experiments were carried out in wild type or pAlb 3-month-old female C57BL/6J
(CD45.1/Ly5.1 or CD45.2/Ly5.2) mice bred at Scripps Research Division of Animal
Resources Facility (DAR). Mice were housed at ambient temperature and humidity
on a 12 h light cycle. Not more than 5 mice or less than 2 mice were housed
together. All procedures were performed on animals anesthetized using isoflurane.
Cas9-RNP selection. gRNAs targeting the IgH-J4 and IgK-J5 region of the refer-
ence C57BL/6J genome (GRCm38) were designed using the GPP webtool (https://
portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). The gRNAs
were synthesized by IDT (as crRNAs). CRISPR-Cas9 tracrRNA and HiFi Cas9
nuclease V3 were purchased from IDT (#1072534, #1081061). Cas9:crRNA:
tracrRNA complexes were made according to the manufacturer’s instructions. The
targeting efficiency of different gRNAs was directly assessed by VRC01 engineering
efficiency in LPS-activated primary B-cells (described below) and the best gRNAs
were chosen for IgH-J4 and Igk-J5 targeting. Individual gRNA targeting efficiencies
were assessed by transfecting each one into cells as RNPs. After 48 h of culture,
gDNA was purified (Qiagen 69504) and amplicons of the target cut sites generated
by PCR (H target PCR primers: forward 5′-tcttgtgtgacaccaggaattggcat-3′, reverse 5′-
cctccagccataggattgttttagca-3′. k target PCR primers: forward 5′-cttgtgtgaatttgtga-
cattttggct-3′, reverse: 5′-acgtctagaagaccacgctacctgca-3′). PCR products were pur-
ified (Qiagen, 28004) and Sanger sequenced (Eton Bioscience) using both forward
and reverse primers (H target sequencing primers: forward 5′-ggaaaaatccactattgt-
gattactatgct -3′, reverse 5′-cccatcatccagggactccaccaaca-3′. k target sequencing pri-
mers: forward 5′-agaaaagagtcagtgtgaaagctgagcga-3′, reverse: 5′-
ttctccgatccaatctcttggatggtg-3’). Chromatograms were uploaded into TIDE for
INDEL analysis as instructed by the developer (http://shinyapps.datacurators.nl/
tide/)21.
HIV bnAb donor DNA preparation. H-targeting VRC01 donor DNA was
designed as follows from 5′ to 3′: (1) 498-basepair (bp) homology arm upstream of
the mouse IgH-J4 (in germline configuration). (2) The mouse IgHV1−82 HC
promoter region (entire 5′-UTR). (3) The mouse IgKV4-53 leader (intron removed)
and human VRC01 light-chain variable gene followed by the mouse κ constant
region without stop codon. (4) A GSG linker followed by the P2A self-cleaving
peptide sequence. (5) The mouse IgHV1−82 leader lacking the intron followed by
the human VRC01 heavy-chain variable gene and constant gene donor splice site.
(6) A 500-bp region of DNA homologous to the IgH-J4 intron beginning after JH4.
The homology regions and V-gene promoter were amplified from B6 gDNA. The
VRC01 LC-P2A-HC VDJ gene was synthesized (Geneart). H+ κ targeting donor
plasmids were designed as follows: The H-targeting plasmid was modified by the
deletion of the LC and P2A peptide and adding in the IgHV1-82 intron. The LC
donor DNA was designed as follow from 5′ to 3′: (1) 510 bp homology arm
upstream of the mouse IgK-J5; (2) the mouse IgKV4-53 LC promoter (entire 5′
UTR), leader and V-gene intron; (3) VRC01 VJ and constant gene donor splice site
(4) a 510 bp region downstream of Jκ5. All fragments were assembled using Gibson
assembly (NEB, #E5510S) according to the manufacturer’s instructions into the
PICOZ (PMID: 31124712) carrier vector synthesized from IDT and transformed
into DH5a E. coli. (NEB, C2987H). Single colonies from bacteria plated on agar
containing Zeocin were cultured; plasmids were isolated (Qiagen, #27106) and
sequenced (Eton Biosciences) using several primers to generate high-quality cov-
erage of the entire donor DNA region. Donor DNA plasmids were purified using
EndoFree plasmid maxi kit (Qiagen, #12362) for engineering experiments.
B-cell activation and engineering. All work was conducted under sterile condi-
tions. B-cells isolated from the spleens of CD45.1 or CD45.2 congenic mice using
negative selection (Miltenyi, #130-090-862) were cultured in RPMI-1640 (Invi-
trogen, #21870076) supplemented with 1X NEAA (Invitrogen, #11140050), 1X
sodium pyruvate (Invitrogen, #11360070), 55 μM 2-Me (Invitrogen, #21985023),
10% FBS (Invitrogen, #26140-079) and either (1) 50 μg/ml LPS (Sigma, #L2880-
100MG) or (2) CpG ODN 2006 at 1 μM (Synthesized from IDT), IL-4 at 50 ng/ml
(Biolegend, #574306), anti-CD40 at 5 μg/ml (Thermo, #16-0401-86) for 30 h. The
Alt-R CRISPR-Cas9 system components (IDT) were used to make Cas9-RNP
complexes according to the manufacturer’s instructions. gRNA sequences for H or
κ targeting were 5′-gagaggccattcttacctg-3′ and 5′-ttacgtttcagctccagct-3′ respectively.
Activated cells were washed three times with 1X DPBS (Invitrogen, #14190-144)
and resuspended at 5 million cells/ 100 μl in Neon R buffer (Invitrogen,
#MPK10096). For H-targeting, 5 μl H-targeting Cas9-RNP complexes, 2.16 μl 100
μM CRISPR electroporation enhancer (IDT), and 20 μg donor DNA (4 μl) were
mixed and added to the resuspended cells. For H+ κ -targeting, 5 μl each of H- and
κ- targeting Cas9-RNP complexes, 4.32 μl 100 μM CRISPR electroporation
enhancer (IDT), and 15 μg each of HC and LC donor DNAs were mixed and added
to the resuspended cells. The cells were electroporated using a 100 μl tip (Invi-
trogen, MPK10096) with 1650 V, 20 ms, 1 pulse. Nucleofected cells were imme-
diately cultured in media without antibiotics or cell activation components for 1 h
before these components were added for further ex vivo culture. When donor DNA
was transduced into cells as AAV, VRC01 AAV2 donors produced by Vector
Biolabs using the same H-targeting design were used. Cells were at a concentration
of 1 million in 10 μl RPMI-1640 serum-free media were mixed with equal volumes
AAV at an MOI of 2 × 105 for 1 h, then electroporated as described above.
Adoptive transfer of engineered cells. Eighteen hours after transfection, acti-
vated mock or engineered cells were washed four times with DPBS (Invitrogen,
#14190-144) for adoptive transfer into recipient mice. Some cells were further
cultured to confirm the quantity of successfully targeted cells by flow cytometry 48-
h post-transfection. VRC01-engineered B cells were identified by staining for viable
(propidium iodide negative), eOD-GT8+, eOD-GT8-KO11− cells. In some
experiments (Table S1), successfully targeted cells were enriched by FACS before
transfer 18-h post-transfection by gating the live, GT8++KO11− population. To
prepare eOD-GT8 probes, 1.1 μg of biotinylated GT8-monomer (biotinylated using
the EZ-link NHS-Biotin from Thermofisher) was mixed with 0.88 μg streptavidin-
488/647.
Immunization of rested cells. 4 million H+ κ targeted VRC01 cells or 1 million
H-targeted VRC01 cells (corresponding to 40,000 VRC01-expressing engineered
cells by either strategy) were retro-orbitally transferred into recipient mice. These
mice were rested for 14 d before immunization with a 200 μl mixture of 20 μg
immunogen and either Ribi adjuvant (according to the manufacturer’s instructions,
Sigma, #S6322-1VL) or 5 μg of IscoMPLA (kindly provided by the lab of Darrell
Irvine at MIT) in DPBS administered by i.p. injection. Mice were boosted with the
same immunogen 6, 13, and 32 weeks after priming. Serum samples were collected
through ocular bleeding of mice at the time intervals indicated in Fig. 2. All
procedures were done on isoflurane-anesthetized mice.
Immunization of T-primed cells. Recipient mice were i.p. immunized with 200 μl
mixture of 10 μg of either the lumazine synthase or ferritin base in DPBS and Ribi
adjuvant. 7 days later, targeted cells containing 65,000 VRC01-expressing engi-
neered cells were retro-orbitally transferred into pre-primed host mice. Lumazine
synthase pre-primed mice were immunized with 20 μg eOD-GT8-60mer and fer-
ritin pre-primed mice were given 20 μg MD39-ferritin immunogen in Ribi adjuvant
at the same time. For the FACs enriched group, 300,000 sorted antigen-specific
cells were transferred into recipient mice following the same manner of T-primed
immunization. All procedures were done on isoflurane-anesthetized mice.
Flow cytometry analysis and single-cell sorting. Spleen suspensions were gen-
erated by smashing the spleen between frosted glass slides. Bone marrow was
released from tissue-free tibia and femurs by a mortar-and pestle. Red blood cells
(RBCs) were lysed with ammonium chloride (0.83%) before filtering cells through a
40 μM cell strainer to generate single-cell suspensions. Fc Blocker (homemade mAb
2.4g2) was added to single-cell suspensions at 0.5 μg per 106 cells before antibody
staining. For antigen-specific analysis, biotinylated AviTagged GT8 monomers
were pre-complexed for 30 min to Streptavidin-AF488 (Thermo, #S32354) or
Streptavidin-AF647 (Thermo, #S32357); GT8-KO11 was complexed to
streptavidin-BV421 (BD, #BDB563259). Fluorophore-conjugated antibodies
CD45.1 (Biolegend, #110728), CD45.2 (Biolegend, #109806), GL7 (Biolegend,
#144608, #144610) TCRb (Biolegend, #109228), F4/80 (Biolegend, #123128),
Ter119 (Biolegend, #116228), CD38 (Biolegend, #102718), IgD (Biolegend,
#405710), IgM (Biolegend, #406512), IgG1 (Biolegend, #406620), CD138 (Biole-
gend, #142504), Sca-1 (Ly6A/E) (Biolegend, #122512) and CD19 (Biolegend,
#152408), CD80 (Biolegend, #104712), CD73 (Biolegend, #127210), PD-L2 (Bio-
legend, #107216), anti-mouse Kappa (Clone 187.1 AF647), Anti mouse Lambda
(Biolegend, #407306) were used to define different cellular populations. CD45.1
and CD45.2 mAbs were used to distinguish host and transferred B-cells.
IgG1 staining was used to identify class-switched B-cells. VRC01 expressing
memory cells (MCs) were gated as live GT8+KO11−CD19+CD38highsIgD−GL7−;
Germinal center (GC) B-cells were gated as live CD19+ CD38−GL7+; Plasma cells
(PCs) were gated as CD138+ Sca1+TCRb−Ter119−sIgD−sIgM−GL7−F4/80−;
Permeabilized surface-stained PCs were intracellularly stained with GT8, KO11
and IgG1 probes. Antibody stains were all diluted 100× into the cell sample. Cells
were analyzed using the LSR II (BD Biosciences), the Aurora (Cytek), or sorted
using a BD FACSAria (BD Biosciences) at the Scripps Flow core. FlowJo v10.7 was
used to analyze all flow cytometry data and to generate figures.
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Allelic inclusion. To assess the surface expression of endogenous LCs in engi-
neered VRC01+ cells, B cells from knock-in mice expressing LCs with only human
κ constant chains33 were purified, activated, and engineered using the H-targeting
strategy. Fc Blocker (homemade mAb 2.4g2) was added to single-cell suspensions
at 0.5 mg per 106 cells before antibody staining. The engineered B cells were stained
with anti-mouse Kappa (BD, #561353), anti-human Kappa (Biolegend, #316506),
anti-mouse Lambda (Biolegend, #407308), eOD-GT8-AF647 tetrameter and ana-
lyzed by FACS.
Peripheral tolerance. Eight million B cells isolated from the spleens of CD45.2
congenic mice using negative selection (Miltenyi, #130-090-862) were either
transferred directly or after 24 h of ex vivo LPS-activation into CD45.1 pAlb and
WT recipient mice at day 0. Before adoptive transfer, the frequency of B cells
carrying κ LC were determined using an AF647-labeled anti-κ antibody (home-
made) by flow cytometry. The κ frequency of CD45.2 (donor) from splenic B cells
of recipient mice were analyzed successively on day 1, 8, 15, and 28 post transfer.
Total response ELISA. 384-well ELISA plates (Corning, #3700) were initially
coated with 12.4 μl/well streptavidin (Jackson Immuno Research Labs, #016-000-
084) at 2 μg/ml diluted in PBS and incubated at 4 °C overnight. Plates were
washed 3× with 100 μl/well PBS containing 0.05% Tween (PBS-T) and blocked
with 40 μl/well PBS+ 3% BSA at RT for 1 h before the addition of 12.4 μl/well
biotin-labeled BG505 SOSIP (produced in house, Pugach et al., Journal of Virology,
2015) at 2 μg/ml diluted in PBS-T and 1% BSA. Mouse sera were serially diluted
(3×) using PBS-T and 1% BSA starting at 1:10 and 12.4 μl/well incubated at room
temperature (RT) for 1 h. After washing (as above), 12.4 μl/well alkaline
phosphatase-conjugated goat anti-mouse IgG (H+ L) (Jackson Immuno Research
Labs, #115-055-146) diluted 1:5000 in PBS-T, 1% BSA was added and incubated for
30 min at RT. Plates were washed and p-nitrophenyl phosphate (pNPP) substrate
(Sigma Aldrich, #S0942) dissolved to 1 mg/mL in substrate buffer (10 mM MgCl2
with 80 mM Na2CO3 and 15 mM NaN3, pH 9.8), was added at 12.4 μl/well to
visualize the binding of antigen-specific mouse IgG. Optical density (OD) at
405 nm was read on a SpectraMax Plus (Molecular Devices) plate reader, allowing
the same amount of development time for each plate. EC50 values were generated
by fitting curves to plots of Absorbance values vs. the log of the serum dilution for
each sample.
Anti-P2A ELISA. 384-well plates were pre-coated overnight at 4 °C with 12.4 μl/
well, 2 μg/ml BG505 SOSIP 2JD6 nanoparticle produced in house34. Plates were
washed and blocked with 40 μl/well of PBS supplemented with 3% BSA at RT for
1 h and washed again. Mouse serum samples serially diluted (2×) with PBS-T and
1% BSA starting at 1:10 dilution were added (12.4 μl/well) and incubated at RT
for 1 h. A P2A-LC tagged mouse VRC01 IgG monoclonal antibody standard
starting at 1 μg/mL was also added (12.4 μl), serially diluted (2×), and incubated at
RT for 1 h. Plates were washed and incubated with 12.4 μl/well biotin-labeled anti-
2A peptide (3H4) mouse antibody (NovusBio, #NBP2-59627) at 1 μg/ml in PBS-T
and 1% BSA. Plates were washed and the captured complex incubated with 12.4 μl/
well alkaline phosphatase-conjugated Streptavidin (Jackson Immuno Research
Labs, #016-050-084) at 1:3000 dilution in PBS-T and 1%BSA at RT for 1 h. Plates
were washed and pNPP substrate was added as above. All plates developed for the
same period of time before being read at 405 nm as above. P2A titers were reported
as area under the curve for plots of Absorbance vs. log dilution factor for each
sample. When maximum Abs 405 nm values were above 1.5, P2A-antibody
quantities in serum samples were calculated by multiplying the sample EC50 with
that of the mouse-VRC01 standard.
Mouse VRC01−P2A IgG preparation. The VRC01 LC-P2A-HC construct was
PCR-amplified from engineered C57BL/6J mouse cDNA and cloned between the
promoter and constant regions of a mouse IgG2b HC expression vector (Invivo-
Gen, #pfuse-mchg2b) using Gibson Assembly. A leader sequence (5′-ATGGGA
TGG TCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTACATT
CA-3′) was also incorporated 5′ to the LC region. Transient expression of the P2A-
VRC01 antibody was accomplished through transfection into FreeStyle™ 293-F cells
following manufacturer’s guidelines. The supernatant was harvested 5 days post
transfection and IgG was affinity purified using Protein A Sepharose (GE
Healthcare, #17−5280-02). SDS-PAGE was used to confirm the purity of IgG and
adequate cleavage of the P2A peptide. The activity of the antibody was comparable
to the human VRC01 IgG monoclonal antibody in virus neutralization assays.
Competition ELISA. 384-well plates were pre-coated overnight at 4 °C with 12.4 μl
of BG505 SOSIP 2JD6 at 2 μg/ml diluted in PBS. After washing and blocking,
12.4 μl/well of mouse sera serially diluted (2×) in PBS-T and 1% BSA (starting at
1:10) was added to plates and incubated at RT for 1 h. 12.4 μl/well of human
VRC01 monoclonal antibody at 200 ng/ml was then added directly to the diluted
sera. Plates were incubated for another hour after mixing and non-binding anti-
bodies were washed away. Captured antibodies were detected with alkaline
phosphatase-conjugated goat anti-human IgG, Fcγ fragment specific (Jackson
Immuno Research Labs, #109-055-098) diluted 1:5000 in PBS-T and 1% BSA.
Plates were incubated at RT for 1 h before the addition of pNPP substrate as
described above. OD values at 405 nm were read, and standard curves were gen-
erated. Absorbance values were transformed by taking the absolute value of the
(sample Abs 405 nm minus the Abs 405 nm of non-competing negative control
wells). The area under the curve was then generated from Abs vs log serum
dilution plots.
Neutralization assay. Under sterile BSL2/3 conditions, PSG335 plasmid was co-
transfected into 293T cells along with various HIV envelope plasmids31 using
Lipofectamine 2000 transfection reagent (ThermoFisher Scientific, #11668019) to
produce single-round of infection competent pseudo-viruses representing multiple
clades of HIV. 293T cells were plated in advance overnight with DMEMmedium+
10% FBS+ 1% Pen/Strep+ 1% L-glutamine. Transfection was done with Opti-
MEM transfection medium (Gibco, #31985) using Lipofectamine 2000. Fresh
medium was added 12 h after transfection. Supernatants containing the viruses
were harvested 72 h later. In sterile 96-well plates, 20 μl of virus was immediately
mixed with 20 μl of serially diluted (3×) purified IgG from mouse sera (starting
at 400 μg/ml) and incubated for one hour at 37 °C to allow for antibody neu-
tralization of the pseudoviruses. 5000 TZM-bl cells/well (in 40 μl of media con-
taining 100 μg/ml Dextran) were directly added to the antibody virus mixture.
Plates were incubated at 37 °C for 48 h. Following the infection, TZM-bl cells were
lysed using 1× luciferase lysis buffer (25mM Gly-Gly pH 7.8, 15mMMgSO4, 4 mM
EGTA, 1% Triton X-100). Neutralizing ability disproportionate with luciferase
intensity was then read on a Biotek Synergy 2 (Biotek) with luciferase substrate
according to the manufacturer’s instructions (Promega, #PR-E2620).
Engineered B cell immunoglobulin repertoire sequencing and analysis. Cells
were released from mouse spleen and lymph nodes by pressing these tissues
through a 0.2 μm cell strainer using a rubber syringe plunger and rinsing them into
a 50 ml falcon tube using MACS buffer (PBS+ 2%FBS+ 2 mM EDTA). Bone
marrow was obtained by crushing tissue-free tibia and femur bones with a mortar
and pedestal and rinsing the released cells through a 0.2 μm cell strainer into a
50 ml falcon tube. Cells were pelleted by centrifugation (600 × g for 6 min). RBCs
were disrupted by resuspending the cell pellets in 10 ml of RBC lysis buffer
(155 mM NH4Cl+ 12 mM NaHCO3+ 0.1 mM EDTA) for 3 min at RT. Cells were
then diluted to 50 ml with MACS buffer and pelleted. The cells were washed with
50 ml of MACS buffer and cell numbers determined using a Coulter Particle
Counter. We routinely obtained ~1–1.4 × 108 cells from the spleen and lymph node
samples, and roughly 6–9 × 107 cells from the marrow. Cells were pelleted and
resuspended in 100 μl MACS buffer/107cells. 0.5 μg of FcR blocking reagent was
added per 106 cells and the mixture incubated for 10 min at RT. 106 cells were kept
for FACS analysis. The remaining cells were then labeled with biotinylated anti-
CD45.2 Ab (Clone 104, Biolegend, #109804) at a 1:100 dilution for 30 min. The
cells were then washed twice with 1–2 ml MACS buffer per 107 cells. Cell pellets
were resuspended in 70 μl MACS buffer and 20 μl of anti-biotin microbeads
(Miltenyi, #130-090-485)/107 cells. The suspension was well mixed by pipetting
and incubated for 15 min at 4 °C. The cells were washed by adding 1–2 ml of
MACS buffer per 107 cells and pelleted. Cells were then resuspended in 500 μl of
MACS buffer and pipetted onto a MACS buffer rinsed LS column (Miltenyi, #130-
042-401) placed in a magnet field to retain labeled cells on the column. The column
was rinsed 3 × 3ml MACS buffer. The column was then removed from the magnet
and labeled cells eluted into a falcon tube with 7 ml MACS buffer pushed through
the column with a plunger. These cells were then subjected to a second round of
purification over a new LS column. Cell numbers were measured and cells pelleted
for mRNA purification. We routinely obtained ~4–6 × 106 and 2–4 × 106 cells for
spleen/lymph node or bone marrow-derived cells respectively. 105 cells were kept
for FACS analysis. mRNA was purified using the Qiagen RNeasy micro kit (Qia-
gen, #74004) according to the manufacturer’s instructions. mRNA was immedi-
ately subjected to reverse transcription using the Superscript III first-strand
synthesis kit (Thermo) to generate cDNA following the manufacturer’s instruc-
tions. For the RT-PCR we used either a VRC01-specific primer (5′-CCATCTCA
TCCCTGCGTGTCTCCGAC NNNNNNNN GATGAGACGATGACCG -3′) or a
mixture of isotype (IgM, IgA, IgE, IgD & IgG) specific primers (PID_mIgM- CCA
TCTCATCCCTGCGTGTCTCCGAC NNNNNNNN CTGGATGA CTTCAGT
GTTGT; PID_mIgA- CCATCTCATCCCTGCGTGTCTCCGAC NNNNNNNN
CCAGGT CACATTCATCGTG; PID_mIgE- CCATCTCATCCCTGCGTGTCT
CCGAC NNNNNNNN GTTCA CGTGCTCATGTTC; PID_mIgD− CCATCTCA
TCCCTGCGTGTCTCCGAC NNNNNNNN GCCAT TTCTCATTTCAGAGG;
PID_mIgG12- CCATCTCATCCCTGCGTGTCTCCGAC NNNNNNNN KK
ACAGTCACTGAGCTGCT; PID_mIgG3− CCATCTCATCCCTGCGTGTCTCC
GAC NNNNNNNN GTACAGTCACCAAGCTGCT) containing unique primer
IDs (PID) and a primer landing site. All primers for cDNA synthesis were HPLC
purified. The PID were tagging each RNA template with a unique 8−nucleotide-
long identifier, which allowed us to group amplified sequences for each individual
template. The primer landing site was used for the reverse primer binding site of
the subsequent hemi-nested PCRs. The resulting cDNA was purified using
AMpureXP beads (Beckman Coulter, #A63882) at a volume ratio of 1:1. The
purified cDNA was amplified and barcoded during a hemi-nested PCR using the
forward primers VRC01_L1-F (5′-GGATTTTCATGTGCAGATTTTCAGCTT
CATGC-3′) for the first round and the primer VRC01_Junc-F (5′-CAGTGTCACA
GTCATATTGTCCAGTGG-3′) for the 2nd round PCR in combination with the
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reverse primer PID-R (5′-ATCCCTGCGTGTCTCCGAC -3′), that attached to the
primer landing site. Successful amplification was confirmed on a 0.7% agarose
gel and amplicons were barcoded during an additional second round PCR using
a barcoded second round primer set. The final barcoded amplicons were
quantified using the Tapestation D5000 ScreenTape System (Agilent) and pooled at
equimolar ratios. Library preparation and sequencing of SMRTbell template
libraries of ~1.5 kb insert size were performed according to the manufacturer’s
instructions on a PacBio instrument (Pacific Biosciences) at the Salk Institute. Data
were processed and visualized using a pipeline built for this sequencing protocol in
the Julia language, using NextGenSeqUtils36. In brief, samples were first demulti-
plexed and oriented using demux_dict(), and reads were dereplicated. Sequences
were collapsed by primer ID (UMI), and if sequences with the same PID differed,
either due to sequencing error or PID “clashes”37 we retained the most frequent
variant. This gives us a dataset at the “transcript level”. To exclude PacBio or RT
indel errors, we discard reads with any indel variation relative to the engineered
reference. For isotype mixture RT sequencing, we perform isotype calls on tran-
scripts by matching the sequence immediately 3′ of the engineered polypeptide
against isotype references extracted from the CH1 IMGT database, discarding
transcripts that do not match, or match ambiguously. We then collapse “tran-
scripts” into “variants” (sequences with 100% identical nucleotides over the poly-
peptide region, and, in the isotype RT datasets, identical isotype calls), retaining a
transcript count for each variant. These variants, and their associated frequencies,
were used in all sequence analyses (always including the variant frequency when
counting any mutations). For phylogenetic analysis, but nowhere else, we addi-
tionally collapse any “singleton” variants (where frequency= 1) into larger variants
of the same isotype that are just one nucleotide distance from them (we retain
singletons that are >1 nucleotide from their nearest variant). This allows for
compact display of phylogenies. Maximum likelihood phylogenetic trees were
inferred using FastTree238, and visualized using FigTree (http://tree.bio.ed.ac.uk/
software/figtree/). Curated data were also analyzed using Geneious 11.0.5.
Statistical analysis. Statistical analysis used an unpaired two-tailed T test (Prism,
Graphpad). Correlation between EC50 of P2A titers and the relative concentration
of VRC01 was calculated using the Pearson correlation coefficient with linear
regression (Prism, Graphpad). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Annotated donor DNA sequences are available in GenBank under accession codes
MT789856, MT789857, and MT789858. Raw flow cytometry data that support the
findings of this study are available from the corresponding author (J.E.V.) upon
reasonable request. Raw PacBio data (Fig. 4, Supplementary Figs. 6 and 7) are available
from the corresponding author (B.M.). All other data are available in the article and
supplementary files or from the corresponding author J.E.V. upon reasonable
request. Source data are provided with this paper.
Code availability
NGS analysis code and intermediate data processing steps are available in GitHub
(https://github.com/MurrellGroup/EngineeredBCRseq/).
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